The effects of parenteral prostacyclin therapy as add-on treatment to oral compounds in Eisenmenger syndrome.

Abstract

Pulmonary arterial hypertension (PAH) therapy has revolutionised the therapy of patients with Eisenmenger syndrome. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: Dr. D'Alto reports grants and personal fees from Actelion, grants and personal fees from Pfizer, grants and personal fees from GlaxoSmithKline, grants and personal fees from Dompe, grants and personal fees from Bayer/MSD, outside the submitted work. Conflict of interest: Dr. Constantine reports grants from Actelion, outside the submitted work. Conflict of interest: Dr. Balint reports personal fees from Actelion, personal fees from Lilly, personal fees from AOP Orphan, personal fees from Bayer/MSD, outside the submitted work. Conflict of interest: Dr. Romeo reports grants and personal fees from GlaxoSmithKline, grants and personal fees from Dompe, grants and personal fees from MSD, outside the submitted work. Conflict of interest: Dr. Argiento reports grants and personal fees from GlaxoSmithKline, grants and personal fees from Dompe, grants and personal fees from MSD, outside the submitted work. Conflict of interest: Dr. Ablonczy has nothing to disclose. Conflict of interest: Dr. Skoro-Sajer reports grants and personal fees from AOPOrphan Pharmaceuticals, grants and personal fees from Actelion, grants and personal fees from Bayer, grants and personal fees from GlaxoSmithKline, grants and personal fees from Pfizer, grants and personal fees from United Therapeutics, outside the submitted work. Conflict of interest: Dr. Giannakoulas reports grants and personal fees from Actelion, grants and personal fees from United Therapeutics, grants and personal fees from Pfizer, grants and personal fees from GlaxoSmithKline, grants and personal fees from Bayer/MSD, grants and personal fees from Pfizer, grants and personal fees from Lilly, outside the submitted work. Conflict of interest: Dr. Dimopoulos reports grants, personal fees and non-financial support from Actelion, personal fees from Pfizer, personal fees from GlaxoSmithKline, personal fees from Bayer/MSD, outside the submitted work.